CHF 1.3 million Seed funding for Bionomous

Please login or
register
10.09.2021
Bionomous team
Bionomous, the Swiss-based startup who builds devices to automate processes in Life Science research, announces today it has raised a CHF 1.3 million Seed funding round led by Nivalis Group, with participation from SICTIC business angels and Venture Kick.

Experts in mechatronics, microfluidics and machine learning, Swiss biorobotics startup Bionomous develops the EggSorter, a device that automatically inspects, sorts and dispenses small biological entities like the eggs of zebrafish, a small freshwater fish native to South Asia. Its eggs are particularly suited for research in the Life Sciences industry, to find new treatments, perform toxicology tests or better understand the biology and genetics of living organisms. With the EggSorter, laboratories can standardize all processes and increase research throughput.

The investment led Nivalis Group and joined by SICTIC business angels and Venture Kick marks the start of a new development phase for Bionomous. Nivalis Group CEO Nicolas Corsi explains why they have taken an interest: “We are confident that Bionomous is a great addition to the Nivalis Group family. With this investment we ticked off all the boxes we look for in a startup: a growing market segment, a product with excellent traction, a great team, and several underlying technologies that match our existing investments and allow us to create interesting synergies.”

For the SICTIC investors, the reasons to invest are clear. In the words of Marcel Egger, lead SICTIC investor: “We found during our talks and in the due diligence process a great team with the right attitude. The product has numerous existing and future possible expansions in a promising technology in the medical, pharma research and numerous other fields. We are looking forward to contributing to this exciting venture!”

Market interest breeds perspectives

The closing of this Seed funding round allows Bionomous to accelerate the testing phase, to develop a certified product ready-for-market, and to prepare for industrialization. Frank Bonnet Bionomous CEO & co-founder explains: “Our team has demonstrated its capacity to develop products tailored to the specific needs of our customers. This new investment, in addition to the interest of early adopters and the first confirmed orders we received despite the COVID pandemic, allow us to confidently move to the next development phase of our final product and to target a commercialization over the next two years.”

Ana Hernando, Bionomous CMO & co-founder, adds: “Leaders in the zebrafish field have expressed great interest in the EggSorter, which gives us the confidence to launch it to the market. Furthermore, we have received several requests to use our technology in other fields such as personalized medicine, diagnostics and aquaculture. Thanks to this investment round, our team can explore the possibilities to apply our technology to other segments and study new opportunities to diversify our product lines.”

(Press release)

0Comments

More news about

Bionomous SA

Company profiles on startup.ch

Bionomous SA

rss